Delivery Order SPE2DB20D3304-SPE2DB25FW9E6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed-price contract valued at $25,599.93, with an ultimate completion date of July 15, 2025. This non-set-aside, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,862.40 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed price contract type. The award, issued on July 9, 2025, with an ultimate completion date of July 10, 2025, represents a non-set-aside competitive procurement. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,827.12 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed-price contract. The delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-competitive, competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) with a ceiling value of $18,978.90. This non-set-aside competitive award is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) valued at $16,636.35 under a firm fixed-price contract. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery of this pharmaceutical product from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $6,133.96 to AmerisourceBergen Drug Corp for Eliquis 5 mg tablets (60-count packages), with an ultimate completion date of August 14, 2025. This non-competitive, firm fixed-price delivery order was issued under a larger Indefinite Delivery Contract (IDC) vehicle—specifically the DLA Troop Support Medical SPE2DX prime vendor contract valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,282.20 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units). The contract, awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a firm fixed-price procurement with no set-aside designation, indicating the award was competitively available. Performance of this delivery order is based in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $10,427.06 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed price contract. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a non-competitive delivery against an existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $19,111.33 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units). This contract, executed on July 29, 2025, with an ultimate completion date of July 30, 2025, utilizes firm fixed-price pricing and was competitively awarded without any set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,063.82 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed-price contract. The delivery order was competitively awarded without set-aside provisions and is scheduled for completion by September 26, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location, leveraging its extensive...
- SPE2DB20D3304Indefinite Delivery Contract
- SPE2DB20D3304-SPE2DB25FW9E6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,066.34 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed price contract. The contract was competitively awarded without set-aside designations and carries an ultimate completion date of September 24, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this order. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. The IDC enables AmerisourceBergen to supply an extensive portfolio of pharmaceutical products and medical supplies to support military healthcare systems globally, including the Defense Health Agency and U.S. Coast Guard. The current award for Eliquis, a brand-name anticoagulant medication, reflects the company's continued role as a critical vendor for federal medical procurement within DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 9/23/25 |